Quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberEMA/CHMP/VWP/141697/2009
Published10/08/2010
Effective from01/01/2011
KeywordsLive recombinant viral vectored vaccine, heterologous antigen
DescriptionThis document provides recommendations on the quality, non-clinical and clinical studies that should be performed in order to obtain marketing authorisation of a live recombinant viral vectored vaccine intended for use in the prophylaxis of infectious disease in humans. Plasmid DNA vaccines, recombinant protein vaccines and vaccines against non-infectious indications, i.e. ‘immunotherapeutic’ medicinal products, are not within the scope of this guideline. Vaccines based upon bacterial vectors such as salmonella and Bacillus Calmette-Guérin are also not within the scope of this guideline, although many of the principles that apply here could also apply to these vaccines.


Document history

First version

Current version

Adopted guideline


Draft guideline


Concept paper

In operation: 01/01/2011–present


Published: 20/04/2009


Published: 16/07/2007


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more